Stuttgart, Germany
The D-Flex® from Haselmeier is a product platform of a new generation of disposable injection pen systems for subcutaneous self-injection.
This next-generation pen system for subcutaneous self-injection bridges the gap between fixed and variable-dose pens and paves the way for connected commercial devices.
The new injection pen won a 2020 Good Design Award from The Chicago Athenaeum.
The patented D-Flex® Technology is bridging the gap between simple fixed dose pens and normal variable-dose pens as known in the Diabetes or Hormone-Therapy.
This innovative technology allows easy adaptation to the titration requirements of drugs for specific therapies where multi distinct fix doses are required.
All essential fix doses can be realized on just one D-Flex® Pen. These doses can be flexible selected
by the customers according to their specific requirements on the titration-scheme of the special drug.
It just needs the modification of just one part of the D-Flex® Pen Platform.
Thus, the customers save time and money in the development of the combination product. Furthermore, the special D-Flex® Technology creates additional value for the patient by preventing injection errors and unintended dosages, thus resulting in an improved patient safety.
Haselmeier, a part of Sulzer AG, is a leading provider of solutions for subcutaneous injection systems for the safe self-administration of liquid drugs.
Designers: Haselmeier AG with Common Sensing Inc.
Manufacturers: Haselmeier AG with Common Sensing Inc.
